Rumore M M, Goldstein G S
Professional Services Department, Sterling Drug Inc., New York, NY 10016.
Drug Intell Clin Pharm. 1987 Dec;21(12):961-9. doi: 10.1177/106002808702101204.
In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina. Clinical trials have demonstrated the efficacy of this drug, especially when treatment is begun soon after the initial event. The antiplatelet actions of aspirin seem to be the most plausible explanation for its efficacy in reducing mortality and the rate of reinfarction. A single daily 325-mg tablet is effective and produces side-effect incidences of only zero to two percent above those produced by placebo. This article assesses the current state of knowledge regarding the value of aspirin therapy in survivors of acute MI and the implications for clinical practice.
1985年10月，美国食品药品监督管理局批准了阿司匹林的一项新适应症，用于心肌梗死（MI）或不稳定型心绞痛患者再次发生心肌梗死和死亡的二级预防。临床试验已证明该药物的疗效，尤其是在初始事件后不久就开始治疗时。阿司匹林的抗血小板作用似乎是其降低死亡率和再梗死率疗效的最合理的解释。每日服用一片325毫克的阿司匹林是有效的，其副作用发生率仅比安慰剂高0至2%。本文评估了目前关于阿司匹林治疗对急性心肌梗死幸存者价值的知识状况以及对临床实践的影响。
